Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition

Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.

(2017) M. S. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of cabozantinib (XL184) in patients with renal cell cancer

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

The novel kinase inhibitor EMD1214063 is effective against neuroblastoma

(2014) Kathy Scorsone et al.   INVESTIGATIONAL NEW DRUGS

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

(2014) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

(2013) David Viola et al.   Future Oncology

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas

(2013) Benedict Yan et al.   JOURNAL OF CLINICAL PATHOLOGY

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

(2013) Stephen T. Keir et al.   PEDIATRIC BLOOD & CANCER

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

(2013) Alexander Drilon et al.   Cancer Discovery

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

(2011) Wendy B. London et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Wendy B. London et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Rochelle Bagatell et al.   JOURNAL OF CLINICAL ONCOLOGY

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells

(2009) Hal E Crosswell et al.   BMC CANCER

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group

(2008) Peter E. Zage et al.   PEDIATRIC BLOOD & CANCER